Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 3 ( July-September, 2016 ) > List of Articles


Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach

Pankaj Manoria, Prabhash C Manoria

Citation Information : Manoria P, Manoria PC. Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach. Hypertens J 2016; 2 (3):145-152.

DOI: 10.5005/jp-journals-10043-0047

Published Online: 01-03-2016

Copyright Statement:  Copyright © 2016; The Author(s).


How to cite this article

Manoria PC, Manoria P, Mishra N. Angiotensin Receptor Neprilysin Inhibitor for the Treatment of Cardiovascular Diseases: A New Approach. Hypertens J 2016;2(3):145-152.

PDF Share
  1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987 Jun;316(23):1429-1435.
  2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 Aug;325(5):293-302.
  3. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 Dec;345(23):1667-1675.
  4. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996 May;334(21):1349-1355.
  5. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 May;344(22):1651-1658.
  6. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 Sep;341(10):709-717.
  7. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail 2013 Jul;6(4):711-718.
  8. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 Sep;371(11):993-1004.
  9. The Canadian Cardiovascular Society Heart Failure Companion: Bridging Guidelines to Your Practice. Can J Cardiol 2016 Mar;32(3):296-310.
  10. J Am Coll Cardiol 2016 May 20. [Epub ahead of print].
  11. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016 Jul;37(27):2129-2200.
  12. Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 1995 Jul;16(Suppl F):4-6.
  13. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation 1993 Jan;87(1):70-75.
  14. Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation. Br J Haematol 2005 Jul;130(1):113-120.
  15. Attenuated natriuretic response to adrenomedullin in experimental heart failure. J Card Fail 2001 Mar;7(1):75-83.
  16. Chronic infusion of bradykinin delays the progression of heart failure and preserves vascular endothelium-mediated vasodilation in conscious dogs. Circulation 2004 Jan;109(1):114-119.
  17. Adre-nomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation 2004 Jul;110(4):426-431.
  18. Increased expression of renal neutral endo-peptidase in severe heart failure. Life Sci 2002 Oct;71(23):2701-2712.
  19. Results of the VMAC trial: vasodilation in the management of acute congestive heart failure. Circulation 2000 Nov;102(22):2794-2794.
  20. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002 Dec;144(6):1102-1108.
  21. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011 Jul;365(1):32-43.
  22. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail 1999 Mar;1(1):67-72.
  23. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002 Aug;106(8):920-926.
  24. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004 Feb;17(2):103-111.
  25. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 2016Jan;9(1). doi:10.1161/CIRCHEART-FAILURE.115.002560.
  26. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012 Oct;380(9851):1387-1395.
  27. Principal results of the prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker measuring arterial stiffness in the elderly (PARAMETER) study. European Society of Cardiology 2015 Congress. London; 2015 Aug 31. Abstract 4143.
  28. UK Heart and Renal Protection (UK HARP-III). Available from: http://www.isrctn.com/ISRCTN11958993.
  29. Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dys-function After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy. Circ Heart Fail 2015 Jan;8(1):71-78.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.